Key takeaways
- • Trial: Retatrutide Phase 2 (obesity) (NCT04881760) — Phase 2, 338 participants over 48 weeks.
- • Drug studied: Retatrutide (investigational) (Retatrutide (investigational)) — FDA-approved branded product.
- • Primary endpoint: Percent change in body weight from baseline to week 24 (with 48-week secondary)
- • Key result: Up to 24.2% mean body-weight reduction at 48 weeks on retatrutide 12mg (highest dose) versus 2.1% on placebo
- • Published: New England Journal of Medicine, 2023.
Study design
Retatrutide Phase 2 (obesity) was a phase 2 randomized controlled trial enrolling 338 participants over 48 weeks. The trial studied Retatrutide (investigational) (Retatrutide (investigational)) for obesity / overweight and was published in New England Journal of Medicine in 2023.
Primary endpoint
Percent change in body weight from baseline to week 24 (with 48-week secondary)
Key results
| Measure | Value |
|---|---|
| Headline result | Up to 24.2% mean body-weight reduction at 48 weeks on retatrutide 12mg (highest dose) versus 2.1% on placebo |
| Mean weight loss (highest dose arm) | 24.2% |
| Participants | 338 |
| Duration | 48 weeks |
| Phase | Phase 2 |
Citation
Retatrutide Phase 2 (obesity). Published in New England Journal of Medicine, 2023.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Retatrutide (investigational) drug page — pricing, FDA status, side effects, alternatives
- All retatrutide (investigational) trials
- GLP-1 clinical trials database
Important: This trial was conducted on the FDA-approved branded product Retatrutide (investigational). Compounded versions of Retatrutide (investigational) have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.